Has Jeffrey Gitt, DO received payments from drug or device companies?

Yes. Drug and device makers reported $1,751,132 in general payments to Jeffrey Gitt, DO across 1,165 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Gitt, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Gitt, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Gitt, DO

Neurology · Phoenix, AZNPI 1831370741

Payments from drug & device makers

$1,751,132in general payments, 2019–2025

Across 1,165 payments — averaging $1503.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$675K
F. Hoffmann-la Roche AG$418K
Genentech, Inc.$234K
Biogen$71K
Sanofi US Services Inc.$68K
EMD Serono, Inc.$53K
plus $231K from 50 others

$8,042in research payments, 2019–2025

Across 7 payments — averaging $1148.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$8K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	87	$674,945
F. Hoffmann-la Roche AG	101	$418,303
Genentech, Inc.	13	$234,437
Biogen	147	$70,932
Sanofi US Services Inc.	7	$68,035
EMD Serono, Inc.	131	$53,392
AbbVie(2 entities)	115	$40,467
Sanofi	91	$38,334
Adamas Pharmaceuticals, Inc.	15	$31,390
AstraZeneca	69	$28,129
Genentech USA, Inc.	58	$27,803
Hoffmann-la Roche Limited	4	$22,392
Roche Products Limited	6	$20,908
Bristol Myers Squibb	42	$6,628
Amgen(2 entities)	37	$5,215
Alkermes, Inc.	1	$3,984
Aesculap, Inc.	1	$1,393
Teva Pharmaceuticals USA, Inc.	57	$762
UCB, Inc.	20	$483
Neurocrine Biosciences, Inc.	23	$475
Mallinckrodt Hospital Products Inc.	8	$302
ANI Pharmaceuticals, Inc.	10	$231
Banner Life Sciences, LLC	15	$198
Acorda Therapeutics, Inc	13	$194
Biohaven Pharmaceuticals, Inc.	9	$177
Grifols USA, LLC	6	$133
Jazz Pharmaceuticals Inc.	7	$132
Lilly USA, LLC	8	$131
Tanabe Pharma America, Inc.	6	$107
Biohaven Pharmaceutical Holding Company Ltd.	4	$101
Johnson & Johnson	7	$100
Mallinckrodt Enterprises LLC	4	$84
E.r. Squibb & Sons, L.L.C.	4	$78
Sunovion Pharmaceuticals Inc.	3	$72
Lundbeck LLC	3	$56
Abbott	2	$54
Harmony Biosciences LLC	2	$50
Medtronic(2 entities)	3	$48
Neurelis, Inc.	2	$42
MDD US Operations, LLC	2	$38
Vertical Pharmaceuticals, LLC	2	$36
Aprecia Pharmaceuticals, LLC	2	$35
Supernus Pharmaceuticals, Inc.	2	$34
Alnylam Pharmaceuticals Inc.	2	$32
SK Life Science, Inc.	2	$31
Assertio Therapeutics, Inc.	2	$28
CSL Behring	1	$25
Arbor Pharmaceuticals, Inc.	1	$24
Otto Bock Healthcare LP	1	$23
Amneal Pharmaceuticals LLC	1	$22
Kyowa Kirin, Inc.	1	$21
GRT US Holding, Inc.	1	$21
TG Therapeutics, Inc.	1	$20
Collegium Pharmaceutical, Inc.	1	$15
Sumitomo Pharma America, Inc.	1	$15
Eisai Inc.	1	$13

How this compares

$1,751,132 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona →

Medicare billing

Part B allowed, 2024

$2,797,000

Medicare patients

104

Services billed

76,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Phoenix

David WeidmanPhoenix$7.4M
Stephen FlitmanPhoenix$4.4M
Barry HendinPhoenix$4.4M
Jeremy ShefnerPhoenix$3M
Danielle CabralPhoenix$2.8M
Suraj MuleyPhoenix$2.8M
Todd SchwedtPhoenix$2.8M
Todd LevinePhoenix$2.7M
Anna BurkePhoenix$2.2M
Maria OspinaPhoenix$2.1M

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →